Medical assessment of adverse health outcomes in Dutch childhood cancer survivors; a nationwide project; DCOG-LATER Q2008 study; Long-term renal effects in Dutch survivors of childhood cancer

Medical assessment of adverse health outcomes in Dutch childhood cancer survivors; a nationwide project; DCOG-LATER Q2008 study; Long-term renal effects in Dutch survivors of childhood cancer - DCOG- LATER Q2008 - renal

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47761

Enrollment

2000

Registered

2015-01-23

Start date

2016-05-04

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

late nefrotoxic effects of treatment for childhood cancer renal damage in long-term survivors of childhood cancer

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All patients who were treated for childhood cancer (before age 18) in one of the seven Pediatric Oncology Centers between 1960 and 2004 and who survived for at least 5 years after diagnosis will be included in the SKION LATER study. Participating centres are located in Amsterdam (VU University Medical Center (VUMC)), Groningen (Children's Cancer Center/ University Medical Center Groningen (UMCG)), Rotterdam (Rotterdam Erasmus MC-Sophia (REMC-S), Nijmegen (University Medical Center Nijmegen (UMCN)), Leiden (Leiden University Medical Center (LUMC) and Utrecht (Princess Máxima Center for Pediatric Oncology (PMC)). From this cohort, 2000 childhood cancer survivors who previously received potentially nefrotoxic treatment will be asked to participate in the DCOG-LATER Q2008 nefrology study.

Exclusion criteria

Exclusion criteria: diagnosis of childhood cancer with survival less than 5 years, age at diagnosis >18 years or diagnosed while residing in foreign country, no nefrotoxic treatment

Design outcomes

Primary

Measure	Time frame
1) Prevalence of glomerular dysfunction in 5-year survivors of childhood cancer treated with possible nefrotoxic modalities (comparisons: high risk versus low-risk group; high-risk group versus reference values from general population; low riskgroup versus reference values general population) 2) Prevalence of tubular dysfunction in 5 year CCS treated with potential nefrotoxic therapy (comparisons: high risk versus low-risk group; high-risk group versus reference values from general population; low riskgroup versus reference values general population) 3) Treatment related-risk factors for abnormal diagnostic renal fucntion tests 4) Hypertension (in relation to glomerular function) 5) Diagnostic value of Cystatin C voor glomerular dysfunctie	—

Measure

Time frame

1) Prevalence of glomerular dysfunction in 5-year survivors of childhood cancer treated with possible nefrotoxic modalities (comparisons: high risk versus low-risk group; high-risk group versus reference values from general population; low riskgroup versus reference values general population) 2) Prevalence of tubular dysfunction in 5 year CCS treated with potential nefrotoxic therapy (comparisons: high risk versus low-risk group; high-risk group versus reference values from general population; low riskgroup versus reference values general population) 3) Treatment related-risk factors for abnormal diagnostic renal fucntion tests 4) Hypertension (in relation to glomerular function) 5) Diagnostic value of Cystatin C voor glomerular dysfunctie

—

Countries

Netherlands

Outcome results